2196 — Shanghai Fosun Pharmaceutical Co Balance Sheet
0.000.00%
- HK$61.79bn
- HK$101.92bn
- CNY41.07bn
- 40
- 38
- 100
- 66
Annual balance sheet for Shanghai Fosun Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | CAS | CAS | CAS | CAS | CAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 10,939 | 13,582 | 16,937 | 15,326 | 15,612 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 6,376 | 8,037 | 9,135 | 9,697 | 10,118 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 25,085 | 30,425 | 35,279 | 33,793 | 34,491 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 13,258 | 14,445 | 17,395 | 23,671 | 23,731 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 83,686 | 93,294 | 107,164 | 113,470 | 117,461 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 24,872 | 29,310 | 33,298 | 33,758 | 37,453 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 46,690 | 54,102 | 62,581 | 67,785 | 70,199 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 36,996 | 39,192 | 44,582 | 45,685 | 47,261 |
| Total Liabilities & Shareholders' Equity | 83,686 | 93,294 | 107,164 | 113,470 | 117,461 |
| Total Common Shares Outstanding |